Diego Vicente Anza-rekin lankidetzan egindako argitalpenak (2)

2005

  1. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point

    International Journal of Antimicrobial Agents, Vol. 25, Núm. 2, pp. 163-167

2001

  1. Prediction of In-vivo efficacy by In-vitro early bactericidal activity with oral β-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin

    Journal of Chemotherapy, Vol. 13, Núm. 2, pp. 118-125